Sei Investments Co. Buys 123,343 Shares of Eli Lilly and Company $LLY

Sei Investments Co. raised its stake in Eli Lilly and Company (NYSE:LLY) by 19.2% during the first quarter, HoldingsChannel reports. The fund owned 767,347 shares of the company’s stock after buying an additional 123,343 shares during the period. Eli Lilly and Company comprises approximately 0.7% of Sei Investments Co.’s holdings, making the stock its 18th largest position. Sei Investments Co.’s holdings in Eli Lilly and Company were worth $705,792,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Brighton Jones LLC lifted its position in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. raised its stake in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC bought a new position in shares of Eli Lilly and Company during the second quarter valued at $356,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at $749,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Neutral Sentiment: Eli Lilly confirmed it will report second-quarter 2026 results on August 5, with a conference call the same day, keeping attention on the company’s upcoming earnings update. Lilly confirms date and conference call for second-quarter 2026 financial results announcement
• Neutral Sentiment: An update on Lilly’s EMPRISE diabetes study added some interest in the company’s clinical data pipeline, but the market’s focus is still centered on the legal battle with Novo Nordisk. Real-World Diabetes Data: What Eli Lilly’s EMPRISE Update Means for LLY Investors
• Positive Sentiment: Broader pharma stocks got a lift after reports that generic drugs imported into the U.S. will remain under a zero-percent tariff for two more years, which could support sentiment across the sector, including Lilly. These major drug stocks rally after Trump’s zero tariff announcement

Analyst Ratings Changes

A number of equities analysts have weighed in on LLY shares. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Guggenheim raised their price target on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Finally, Royal Bank Of Canada raised their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,163.70 on Thursday. The company has a 50-day moving average price of $1,129.17 and a 200-day moving average price of $1,038.31. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $1.10 trillion, a P/E ratio of 41.34, a PEG ratio of 1.49 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 34.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.